

09/971,902

OK to enter  
F-14 09/08/04

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (CURRENTLY AMENDED) A method of decreasing a cytokine mediated hepatic injury response in a mammal comprising administering the peptide shown in SEQ ID NO:1 to the mammal in a pharmaceutically acceptable formulation at a dose and duration to decrease a cytokine mediated hepatic injury response.

2. (ORIGINAL) The method of claim 1 wherein said compound is administered prior to said response.

3. (ORIGINAL) The method of claim 1 wherein said compound is administered subsequent to said response.

4. (ORIGINAL) The method of claim 1 wherein said compound is administered substantially concurrently with said response.

5. (ORIGINAL) The method of claim 1 wherein said compound is administered in the formulation selected from the group consisting of a solution, an emulsion and a suspension.

6. (ORIGINAL) The method of claim 1 wherein said compound is administered parenterally.

7. (ORIGINAL) The method of claim 1 wherein said compound is administered at a concentration in the range of about 0.5 mg/kg to about 20 mg/kg.

8. (CURRENTLY AMENDED) A method for treating hepatic injury in a mammal caused by a chemical toxin comprising administering a pharmaceutically effective concentration of the peptide shown in SEQ ID NO:1 for a duration to treat hepatic injury caused by the chemical toxin.

9. (ORIGINAL) The method of claim 8 wherein the chemical toxin is selected from the group consisting of ethanol, lead, cadmium, carbon tetrachloride, and acetaminophen.

10. (CURRENTLY AMENDED) A method for treating a bacterial or viral infection related hepatic injury in a mammal comprising administering a pharmaceutically effective concentration of the peptide shown in SEQ ID NO:1 for a duration to treat hepatic injury related to the bacterial or viral infection.

11. (ORIGINAL) The method of claim 10 wherein the bacterial or viral infection is caused by an organism selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Neisseria* species, *Salmonella*

species, *Shigella* species, *Escherichia coli*, *Clostridium perfringens*, *Klebsiella* species, *Proteus* species, *Enterobacter* species, *Bacteroides* species, *Brucella* species, *Francisella tularensis*, *Listeria monocytogenes*, *Acinetobacter* species, *Streptobacillus moniliformis*, *Vibrio* species, *Helicobacter pylori*, *Pseudomonas* species, *Haemophilus* species, *Bordetella pertussis*, influenza viruses, adenoviruses, paramyxoviruses, rubella viruses, polioviruses, hepatitis viruses, herpesviruses, rabies viruses, human immunodeficiency viruses and papilloma viruses.

12. (NEW)           The method of claim 1 wherein said compound is administered at least until hepatic function normalizes.